Search Videos and More
News
What is a Menin Inhibitor?
Menin, a protein located in the nucleus of various human cell types, often functions as a tumor suppressor by inhibiting excessive cell growth and division.
News
Dana-Farber Investigators Pinpoint Keys to Cell Therapy Response for Leukemia
Dana-Farber Cancer Institute researchers have identified factors that determine whether donor lymphocyte infusion (DLI), a standard therapy for patients with acute myeloid leukemia (AML) who have relapsed after allogenic hematopoietic stem cell transplant, will successfully move the patient into remission.
Symposium
2024 ASH Highlights
Review presentations and information shared by Dana-Farber physician-scientists at the 67th American Society of Hematology Annual Meeting & Exposition in San Diego on Dec. 1-10th, 2024.
News
Rapid Blood Cancer Diagnostic Could Speed Decisions and Save Lives
Researchers at Dana-Farber Cancer Institute have created a CRISPR-based rapid molecular diagnostic for two forms of leukemia that are driven by mutations that involve gene fusions.
News
Researchers Devise Novel Solution to Preventing Relapse after CAR T-cell Therapy
Even as they have revolutionized the treatment of certain forms of cancer, CAR T-cell therapies have been shadowed by a significant limitation: many patients, including those whose cancer goes into full remission, eventually relapse. In a new study, Dana-Farber Cancer Institute researchers report on a technique with the potential to eliminate that problem.
News
Researchers Customize AI Tools for Digital Pathology
Scientists from Dana-Farber Cancer Institute and Weill Cornell Medicine have developed and tested new artificial intelligence (AI) tools tailored to digital pathology—a relatively new field that uses high-resolution digital images that are created from tissue samples to diagnose diseases and inform treatment decisions.
News
Study Highlights the Importance of Infection Prevention After CAR T-Cell Therapy
A systematic review and meta-analysis of non-relapse mortality after CAR T-cell therapy.
News
Dana-Farber Researchers Discover New Target for Potential Leukemia Therapy
A team of Dana-Farber Cancer Institute investigators discovered that a subset of myeloid and lymphoid leukemias depend on a molecular complex called PI3Kgamma for survival.
News
Unraveling the Menin Mystery to Halt Cancer Growth
The story of research in menin and its relation to cancer — from early efforts to understand how the cell makes use of menin, to explorations of the cell machinery operated by menin, to the development and testing of agents that inhibit menin, to work on preventing resistance to such agents — weaves through Dana-Farber at every step.
News
Ancient DNA Reveals Origin of Racial/Ethnic Disparity in a Childhood Cancer
There are 40% more Hispanic/Latino kids diagnosed with acute lymphoblastic leukemia (ALL) than white non-Hispanic/Latino children; actually, Hispanic/Latino individuals have the highest risk of ALL in the United States. However, the basis for this difference is not well understood. Researchers recently identified a genetic variant that accounts for the increased risk of B-cell ALL in Hispanic/Latino children, and using ancient DNA, they traced the mutation all the way back to the first migrants who entered the Americas ~13,000 years ago.
News
Bispecific Antibody Therapies for Lymphoma
Since 2015, Dana-Farber researchers have been participating in clinical trials that evaluate the use of bispecific antibodies for patients with non-Hodgkin lymphoma. Three bispecific antibody therapies have been FDA approved with more on the horizon. These are exciting new medicines that rally the immune system in a powerful way to fight blood cancers. But rolling out a new type of medicine is a project of its own.
News
BCL2 Inhibitors: What’s the Latest Research?
BCL2 inhibitors are drugs that prompt cancer cells to die by altering the interactions among key proteins within the cells. They were clinically developed, in large part, by researchers at Dana-Farber and have been approved by the U.S. Food and Drug Administration (FDA) for the treatment of acute myeloid leukemia (AML) and chronic lymphocytic leukemia (CLL) in adults.